Show simple item record

dc.contributor.authorJokubaitis, VG
dc.contributor.authorSpelman, T
dc.contributor.authorLechner-Scott, J
dc.contributor.authorBarnett, M
dc.contributor.authorShaw, C
dc.contributor.authorVucic, S
dc.contributor.authorLiew, D
dc.contributor.authorButzkueven, H
dc.contributor.authorSlee, M
dc.identifierpii: PONE-D-12-28643
dc.identifier.citationJokubaitis, V. G., Spelman, T., Lechner-Scott, J., Barnett, M., Shaw, C., Vucic, S., Liew, D., Butzkueven, H. & Slee, M. (2013). The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. PLOS ONE, 8 (3),
dc.descriptionC1 - Journal Articles Refereed
dc.description.abstractOBJECTIVE: To prospectively characterise treatment persistence and predictors of treatment discontinuation in an Australian relapsing-remitting multiple sclerosis (RRMS) population. METHODS: Tertiary MS treatment centres participating in the MSBase registry prospectively assessed treatment utilisation, persistence, predictors of treatment discontinuation and switch rates. Multivariable survival analyses were used to compare treatment persistence between drugs and to identify predictors of treatment discontinuation. RESULTS: 1113 RRMS patients were studied. Patients persisted on their first disease-modifying therapy (DMT) for a median of 2.5 years. Treatment persistence on GA was shorter than on all IFNβ products (p<0.03). Younger age at treatment initiation and higher EDSS were predictive of DMT discontinuation. Patients persisted on subsequent DMTs, for 2.3 years. Patients receiving natalizumab (NAT) as a subsequent DMT persisted longer on treatment than those on IFNβ or GA (p<0.000). The primary reason for treatment discontinuation for any drug class was poor tolerability. Annualised switch or cessation rates were 9.5-12.5% for individual IFNβ products, 11.6% for GA and 4.4% for NAT. CONCLUSION: This multicentre MS cohort study is the first to directly compare treatment persistence on IFNβ and GA to NAT. We report that treatment persistence in our Australian RRMS population is short, although patients receiving IFNβ as a first DMT persisted longer on treatment than those on GA. Additionally, patients receiving NAT as a subsequent DMT were more likely to persist on treatment than those switched to IFNβ or GA. EDSS and age at DMT initiation were predictive of DMT discontinuation. Treatment intolerance was the principal reason for treatment cessation.
dc.subjectNeurology and Neuromuscular Diseases; Nervous System and Disorders
dc.titleThe Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform
dc.typeJournal Article
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentMedicine - Royal Melbourne Hospital
melbourne.source.titlePLoS One
dc.rights.licenseCC BY
melbourne.contributor.authorLiew, Danny
melbourne.contributor.authorButzkueven, Helmut
melbourne.contributor.authorJokubaitis, Vilija
melbourne.contributor.authorSpelman, Timothy
melbourne.contributor.authorKilpatrick, Trevor
melbourne.fieldofresearch320905 Neurology and neuromuscular diseases
melbourne.seocode200199 Clinical health not elsewhere classified
melbourne.accessrightsAccess this item via the Open Access location

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record